Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec/insulin aspart (22011) vs Ryzodeg in type 2 diabetes
CTR20230605Phase 3Completed
- Sponsor
- HEC Pharm
- Start
- Mar 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by HEC Pharm. Started Mar 2023; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20230605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230605.